Corcept Therapeutics (CORT) Earns Daily Media Impact Rating of 0.14
News articles about Corcept Therapeutics (NASDAQ:CORT) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corcept Therapeutics earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.187470114799 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Corcept Therapeutics (NASDAQ CORT) traded up 3.94% during trading on Friday, reaching $18.20. The company had a trading volume of 1,582,183 shares. The stock has a market capitalization of $2.06 billion, a PE ratio of 90.55 and a beta of 2.07. The stock’s 50-day moving average price is $15.54 and its 200-day moving average price is $12.18. Corcept Therapeutics has a 12 month low of $5.94 and a 12 month high of $18.54.
Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.02. The business had revenue of $35.56 million during the quarter, compared to analyst estimates of $31.37 million. Corcept Therapeutics had a return on equity of 51.45% and a net margin of 22.28%. The company’s revenue was up 80.3% compared to the same quarter last year. During the same period last year, the company posted $0.01 EPS. Equities analysts forecast that Corcept Therapeutics will post $0.42 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on CORT shares. BidaskClub cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 15th. Zacks Investment Research cut Corcept Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Ladenburg Thalmann Financial Services set a $20.00 price objective on Corcept Therapeutics and gave the stock a “buy” rating in a report on Tuesday, July 18th. Piper Jaffray Companies set a $18.00 price objective on Corcept Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 24th. Finally, Stifel Nicolaus started coverage on Corcept Therapeutics in a report on Thursday, August 31st. They set a “buy” rating and a $20.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $16.17.
ILLEGAL ACTIVITY NOTICE: “Corcept Therapeutics (CORT) Earns Daily Media Impact Rating of 0.14” was originally published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/23/corcept-therapeutics-cort-earns-daily-media-impact-rating-of-0-14.html.
In other news, Director David L. Mahoney sold 6,091 shares of the firm’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $12.50, for a total transaction of $76,137.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David L. Mahoney sold 23,006 shares of the firm’s stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $12.50, for a total value of $287,575.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,601 shares of company stock valued at $532,513. Corporate insiders own 19.20% of the company’s stock.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.